Health Catalyst (HCAT)

$1.77 +1.14% on the day Market cap $131M 52-week range $0.95 to $3.62 Prices as of Oct 11, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Health Catalyst's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

D

Five factors scored 1 to 9 from HCAT's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation9
Profitability1
Growth0
Financial health4
Cash efficiency0

Results from SEC filings

Fiscal years, from Health Catalyst's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.

Fiscal year20212022202320242025
Revenue$242M$276M$296M$307M$311M
Net income-$153M-$137M-$118M-$70M-$178M
Free cash flow-$34M-$37M-$34M$13M-$237,000
EPS (diluted)-$3.23-$2.63-$2.09-$1.15-$2.55
Operating margin-59.4%-50.7%-42.9%-22.8%-51.7%

Where the revenue comes from

Revenue by segments, fiscal 2025. Every breakdown, year by year.

Technology$208M67%
Professional Services$103M33%

Superinvestors who own HCAT

From each investor's latest 13F filing (what a 13F shows). 1 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Cliff Asness
AQR Capital Management
Trimmed $749,4060.0%Q2 2026

Insider buying

Open-market purchases by Health Catalyst's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

DateInsiderSharesPriceValue
Sep 14, 2026 Simeon Kohl
Chief Executive Officer
59,000$1.79$105,439

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when HCAT trades at or below it.

$

New accounts get 7 days of Pro, price alerts included. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

Are Health Catalyst insiders buying the stock?

1 open-market insider purchase of HCAT in the last 12 months, from SEC Form 4 filings.

Which superinvestors own Health Catalyst?

1 of the superinvestors Investingly tracks hold HCAT in their latest 13F, including Cliff Asness.

Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.